Study Evaluating Etanercept in Moderate to Severe Asthma

A Randomized, Double-Blind, Placebo Controlled Trial Evaluating the Safety and Efficacy of Etanercept 25mg Twice Weekly in Subjects With Moderate to Severe Persistent Asthma

The primary objective of the study is to assess the efficacy and safety of etanercept 25 mg given twice weekly in subjects with moderate to severe persistent asthma.

Inclusion Criteria:

• Moderate to severe persistent asthma for at least 1 year
• Demonstrated reversibility of at least 9% and (FEV1) 50% to 80% predicted
• Subjects must be on a high-dose inhaled corticosteroid (ICS)

Exclusion Criteria:

• Previous treatment with etanercept
• Current use of cigarettes
• Significant concurrent medical conditions at the time of screening